{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_itu2PgFdrjV-docKmLK8Jn5oXe_05RgvQh73eOhI_mE.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_at_symbol.js?nzn7ke\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_article_reference_popup.js?nzn7ke\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_I8yX6RYPZb7AtMcDUA3QKDZqVkvEn35ED11_1i7vVpc.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\n(function(i,s,o,g,r,a,m){i[\u0022GoogleAnalyticsObject\u0022]=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})(window,document,\u0022script\u0022,\u0022\/\/www.google-analytics.com\/analytics.js\u0022,\u0022ga\u0022);ga(\u0022create\u0022, \u0022UA-15605596-27\u0022, {\u0022cookieDomain\u0022:\u0022auto\u0022});ga(\u0022set\u0022, \u0022page\u0022, location.pathname + location.search + location.hash);ga(\u0022send\u0022, \u0022pageview\u0022);ga(\u0027create\u0027, \u0027UA-189672-26\u0027, \u0027auto\u0027, {\u0027name\u0027: \u0027hwTracker\u0027});\r\nga(\u0027hwTracker.send\u0027, \u0027pageview\u0027);\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;12\\\/17\\\/32\u0022},{\u0022requested\u0022:\u0022long\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;12\\\/17\\\/32\u0022}],\u0022ac\u0022:{\u0022spmdc;12\\\/17\\\/32\u0022:{\u0022access\u0022:{\u0022reprint\u0022:true,\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022spmdc;12\\\/17\\\/32\u0022,\u0022atom_uri\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022spmdc\u0022}}},\u0022googleanalytics\u0022:{\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackUrlFragments\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/jquery.cluetip.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.hoverIntent.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.bgiframe.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u00220\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/cdn\/css\/http\/css_Xg7z6oCTVgud_Q0huYz9x9iiD5H_2YPSJ5z2ZViSWdY.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-sageoa-tab-art\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 id=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2\u003ESummary\u003C\/h2\u003E\n            \u003Cp id=\u0022p-1\u0022\u003EThe benefit of oral anticoagulation following acute coronary syndrome (ACS) has been demonstrated in warfarin trials, showing significant reductions in myocardial infarction and stroke at the expense of an increased risk of bleeding. The impact of oral direct thrombin inhibitors and direct factor Xa inhibitors in ACS patients has been the subject of several clinical trials.\u003C\/p\u003E\n         \u003C\/div\u003E\u003Cul class=\u0022kwd-group\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003ECoronary Artery Disease\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003EInterventional Techniques \u0026amp; Devices Thrombotic Disorders\u003C\/li\u003E\u003C\/ul\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-1\u0022\u003E\n         \u003Ch2 class=\u0022\u0022\u003EOral Anticoagulants\u003C\/h2\u003E\n         \u003Cp id=\u0022p-2\u0022\u003EThe benefit of oral anticoagulation following acute coronary syndrome (ACS) has been demonstrated in warfarin trials, showing significant reductions in myocardial infarction (MI) and stroke at the expense of an increased risk of bleeding. The impact of oral direct thrombin inhibitors and direct factor Xa inhibitors in ACS patients has been the subject of several clinical trials that were presented by Christopher B. Granger, MD, Duke University Medical Center, Durham, North Carolina, USA.\u003C\/p\u003E\n         \u003Cp id=\u0022p-3\u0022\u003EIn the Phase III Acute Coronary Syndrome [APPRAISE-2; Alexander JH et al. \u003Cem\u003EN Engl Med\u003C\/em\u003E 2011] study of apixaban combined with antiplatelet therapy in high-risk ACS patients, apixaban was not more effective than placebo (HR, 0.95; 95% CI, 0.80 to 1.11; p=0.51). The study was stopped early because of significantly increased risk of major bleeding with apixaban (1.3%) versus placebo (0.5%; HR, 2.59; 95% CI, 1.50 to 4.46; p=0.001).\u003C\/p\u003E\n         \u003Cp id=\u0022p-4\u0022\u003EThe Efficacy and Safety Study for Rivaroxaban in Patients with Acute Coronary Syndrome [ATLAS ACS 2-TIMI 51] trial randomized patients with recent ACS to rivaroxaban 2.5 mg BID (n=5174), rivaroxaban 5.0 mg BID (n=5176), or placebo (n=5176) [Mega JL et al. \u003Cem\u003EN Engl J Med\u003C\/em\u003E 2012]. The incidence of the primary endpoint of cardiovascular (CV) death, MI, and stroke was 8.9% with rivaroxaban (both doses) versus placebo (10.7%; HR, 0.84; 95% CI, 0.74 to 0.96; modified intention-to-treat [mITT] p=0.008). Patients treated with low-dose rivaroxaban versus placebo had significantly reduced rates of the primary endpoint (9.1% vs 10.7%; HR, 0.84; mITT p=0.02), CV death (2.7% vs 4.1%; HR, 0.66; mITT p=0.002), and all-cause death (2.9% vs 4.5%; HR, 0.68; mITT p=0.002). This survival benefit was not observed with rivaroxaban 5.0 mg. TIMI major bleeding rates were significantly increased with rivaroxaban 2.5 mg (1.8%; HR, 3.46; p\u0026lt;0.001) and rivaroxaban 5.0 mg (2.4%; HR, 4.47; p\u0026lt;0.001) versus placebo (0.6%).\u003C\/p\u003E\n         \u003Cp id=\u0022p-5\u0022\u003EThe What Is the Optimal Antiplatelet \u0026amp; Anticoagulant Therapy in Patients with Oral Anticoagulation and Coronary Stenting [WOEST; \u003Ca class=\u0022external-ref external-ref-type-clintrialgov\u0022 href=\u0022\/lookup\/external-ref?link_type=CLINTRIALGOV\u0026amp;access_num=NCT00769938\u0026amp;atom=%2Fspmdc%2F12%2F17%2F32.atom\u0022\u003ENCT00769938\u003C\/a\u003E; De Wilde W ESC 2012] trial is the first study to compare an oral anticoagulant regimen (warfarin and clopidogrel) with and without aspirin in patients undergoing coronary stenting. Although the trial had some limitations, the double-versus triple-therapy group had significantly lower TIMI bleeding (19.5% vs 44.9%; HR, 0.36; 95% CI, 0.26 to 0.50; p\u0026lt;0.001). Double therapy also appeared to be associated with reduced rates of major adverse cardiac events (MACE; 11.3% vs 17.1%; HR, 0.60; 95% CI, 0.38 to 0.94; p=0.025).\u003C\/p\u003E\n         \u003Cp id=\u0022p-6\u0022\u003EThe APPRAISE-2 and ATLAS-2 trials of novel factor Xa inhibitors in patients also taking aspirin and clopidogrel both demonstrated a 3- to 4-fold increased risk of major bleeding, including intracranial hemorrhage (ICH). Factors such as the dose, patient population, and chance may account for the benefit observed with rivaroxaban but not with apixaban. The WOEST trial has demonstrated the potential for a more favorable benefit\/risk balance by discontinuing aspirin in some patients on oral anticoagulants.\u003C\/p\u003E\n      \u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-2\u0022\u003E\n         \u003Ch2 class=\u0022\u0022\u003EAntiplatelet Agents\u003C\/h2\u003E\n         \u003Cp id=\u0022p-7\u0022\u003ERobert A. Harrington, MD, Stanford University Medical Center, Stanford, California, USA, discussed the current state of adenosine diphosphate (ADP) blockers and emerging approaches to antiplatelet therapy. Antiplatelet therapy is the cornerstone of acute coronary syndrome care, supported by a large body of evidence. Studies have shown that more intense ADP blockade is better than less intense blockade. Although most of the effect is on reduction of MI, the Efficacy and Safety of Adding Clopidogrel to Aspirin or Use of Metoprolol in Myocardial Infarction [COMMIT; COMMIT Collaborative Group. \u003Cem\u003ELancet\u003C\/em\u003E 2005] and PLATO trials showed that mortality reductions are possible. However, balancing efficacy and safety is a challenge, especially with combination therapy.\u003C\/p\u003E\n         \u003Cp id=\u0022p-8\u0022\u003EPatients with ACS, especially those without ST-segment elevation (STEMI) are an increasingly complex group with many variables that must be considered when making treatment decisions, including renal and hepatic function, advanced age, comorbidities, and prior cardiac procedures. Antiplatelet trials have concentrated on early therapy but the risk in patients with non-STEMI accrues over time, with 35% to 40% mortality at 6 to 8 years after the index event.\u003C\/p\u003E\n         \u003Cp id=\u0022p-9\u0022\u003EThe benefits and risks of clopidogrel have been carefully quantified in large randomized trials and through extensive clinical experience. It is an excellent drug but has limitations, including relatively slow onset of action, modest platelet inhibition, and considerable variability in effect based in part on genetic polymorphisms and drug interactions. Prasugrel and ticagrelor have demonstrated efficacy in trials and can be used as alternatives to clopidogrel in some settings. Features of prasugrel and ticagrelor are shown in \u003Ca id=\u0022xref-table-wrap-1-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T1\u0022\u003ETable 1\u003C\/a\u003E.\u003C\/p\u003E\n         \u003Cdiv id=\u0022T1\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u00220 first\u0022\u003E\u003Ca href=\u0022\/\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/14295\/expansion?postprocessors=highwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 html=\u00221\u0022 fragment=\u0022#\u0022 external=\u00221\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00221\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/14295\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_figures%2Chighwire_math%2Chighwire_inline_linked_media\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00222 last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/14295\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 1.\u003C\/span\u003E \n               \u003Cp id=\u0022p-10\u0022 class=\u0022first-child\u0022\u003EFeatures of New ADP Blockers.\u003C\/p\u003E\n            \u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\n         \u003Cp id=\u0022p-12\u0022\u003EThe European and US guidelines have incorporated the following into the latest ACS guidelines:\u003C\/p\u003E\n         \u003Cul class=\u0022list-unord \u0022 id=\u0022list-1\u0022\u003E\u003Cli id=\u0022list-item-1\u0022\u003E\n               \u003Cp id=\u0022p-13\u0022\u003ETreat all patients with aspirin\u003C\/p\u003E\n            \u003C\/li\u003E\u003Cli id=\u0022list-item-2\u0022\u003E\n               \u003Cp id=\u0022p-14\u0022\u003ETreat medium- to high-risk percutaneous coronary intervention (PCI) patients with dual antiplatelet therapy before PCI (clopidogrel, ticagrelor, glycoprotein IIb\/IIIa inhibitors) and at PCI (clopidogrel, ticagrelor, prasugrel, glycoprotein IIb\/IIIa inhibitors)\u003C\/p\u003E\n            \u003C\/li\u003E\u003Cli id=\u0022list-item-3\u0022\u003E\n               \u003Cp id=\u0022p-15\u0022\u003ETreat with dual therapy with aspirin and an ADP blocker when a conservative strategy is used\u003C\/p\u003E\n            \u003C\/li\u003E\u003Cli id=\u0022list-item-4\u0022\u003E\n               \u003Cp id=\u0022p-16\u0022\u003EUse loading doses of ADP blockers.\u003C\/p\u003E\n            \u003C\/li\u003E\u003Cli id=\u0022list-item-5\u0022\u003E\n               \u003Cp id=\u0022p-17\u0022\u003ETreat for at least 12 months\u003C\/p\u003E\n            \u003C\/li\u003E\u003Cli id=\u0022list-item-6\u0022\u003E\n               \u003Cp id=\u0022p-18\u0022\u003EGlycoprotein IIb\/IIIa inhibitors have no benefit in low-risk patients on aspirin\/ADP\u003C\/p\u003E\n            \u003C\/li\u003E\u003Cli id=\u0022list-item-7\u0022\u003E\n               \u003Cp id=\u0022p-19\u0022\u003EPrasugrel is potentially harmful in patients with history of stroke or transient ischemic attack.\u003C\/p\u003E\n            \u003C\/li\u003E\u003C\/ul\u003E\n         \u003Cp id=\u0022p-20\u0022\u003ENew agents in development include cangrelor, a rapid acting IV ADP blocker studied in two randomized trials in patients undergoing PCI. Although cangrelor did not reduce MACE in this setting [Harrington RA et al. \u003Cem\u003EN Engl J Med\u003C\/em\u003E 2009; Bhatt DL et al. \u003Cem\u003EN Engl J Med\u003C\/em\u003E 2009], secondary analyses suggested that cangrelor has benefits in certain contexts. The Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [CHAMPION PHOENIX; \u003Ca class=\u0022external-ref external-ref-type-clintrialgov\u0022 href=\u0022\/lookup\/external-ref?link_type=CLINTRIALGOV\u0026amp;access_num=NCT01156571\u0026amp;atom=%2Fspmdc%2F12%2F17%2F32.atom\u0022\u003ENCT01156571\u003C\/a\u003E] trial is underway to test cangrelor versus clopidogrel in PCI patients. Vorapaxar and other thrombin receptor blockers have been extensively studied. In the Trial to Assess the Effects of SCH 530348 in Preventing Heart Attack and Stroke in Patients with Acute Coronary Syndrome [TRA\u2022CER], vorapaxar added to dual therapy did not reduce MACE and was associated with significantly increased GUSTO moderate\/severe bleeding versus placebo (p\u0026lt;0.001), including increased ICH (p\u0026lt;0.001) [Tricoci P et al. \u003Cem\u003EN Engl J Med\u003C\/em\u003E 2012]. For secondary prevention in subjects with established atherosclerotic vascular disease, the Trial to Assess the Effects of SCH 530348 in Preventing Heart Attack and Stroke in Patients with Atherosclerosis [TRA 2\u00b0P-TIMI 50] demonstrated that the addition of vorapaxar versus placebo reduced the incidence of CV death, MI, or stroke (9.3% vs 10.5%; HR, 0.87; 95% CI, 0.80 to 0.94; p\u0026lt;0.001) but was associated with increased ICH and major bleeding (\u003Ca id=\u0022xref-table-wrap-2-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T2\u0022\u003ETable 2\u003C\/a\u003E) [Morrow DA. \u003Cem\u003EN Engl J Med\u003C\/em\u003E 2012.]\u003C\/p\u003E\n         \u003Cdiv id=\u0022T2\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u00220 first\u0022\u003E\u003Ca href=\u0022\/\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/14297\/expansion?postprocessors=highwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 html=\u00221\u0022 fragment=\u0022#\u0022 external=\u00221\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00221\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/14297\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_figures%2Chighwire_math%2Chighwire_inline_linked_media\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00222 last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/14297\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 2.\u003C\/span\u003E \n               \u003Cp id=\u0022p-21\u0022 class=\u0022first-child\u0022\u003ETRA 2\u00b0P-TIMI 50: Bleeding Endpoints (Overall Population).\u003C\/p\u003E\n            \u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\n      \u003C\/div\u003E\u003Cul class=\u0022copyright-statement\u0022\u003E\u003Cli class=\u0022fn\u0022 id=\u0022copyright-statement-1\u0022\u003E\u00a9 2012 MD Conference Express\u00ae\u003C\/li\u003E\u003C\/ul\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan id=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Ca href=\u0022http:\/\/mdc.sagepub.com\/content\/12\/17\/32.abstract\u0022 class=\u0022hw-link hw-link-article-abstract\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView Summary\u003C\/a\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_openurl.js?nzn7ke\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_tables.js?nzn7ke\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}